JAZZ — Jazz Pharmaceuticals plc

Summary of Jazz Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Jazz Pharmaceuticals reported record total revenue of $4.3 billion for 2025, a 5% increase from 2024. Q4 revenue reached $1.2 billion, reflecting a 10% year-over-year growth.
• Key Product Performances:
  • Xywav: Generated approximately $1.7 billion in 2025, with Q4 revenue of $465 million (up 16% year-over-year).
  • Epidiolex: Achieved $1.1 billion in revenue, marking 9% growth year-over-year; Q4 revenue was $287 million.
  • Modeyso: Launched in August 2025, generating $48 million in revenue by year-end.
  • Zepzelca: Revenue of $307 million for 2025, with Q4 revenue of $90 million (up 15% year-over-year).
• Non-GAAP Adjusted Net Income: Approximately $522 million, with an adjusted EPS of $8.38.

2. Strategic Updates and Business Highlights

• Acquisitions and Approvals: The acquisition of Chimerix facilitated the launch of Modeyso, and Zepzelca received approval for a new indication in October 2025.
• R&D Progress: Significant advancements in the clinical trial of zanidatamab, showing promising data for HER2-positive metastatic gastric and breast cancers.
• Litigation Resolutions: Nearly all major litigation was resolved, including settlements that extend the commercial runway for Epidiolex into the late 2030s.
• Focus on Rare Diseases: Jazz is sharpening its strategic focus on rare diseases, leveraging existing capabilities and expanding into new areas.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected total revenue between $4.25 billion and $4.50 billion, indicating a growth of about 2.5% at the midpoint compared to 2025.
• Product-Specific Expectations:
  • Xywav: Expected to remain flat to grow mid-single digits, with potential declines in revenue from the rare sleep franchise due to competitive pressures from generics.
  • Epidiolex: Anticipated growth primarily from the adult patient population and new formulations.
  • Zanidatamab: Expected to launch in the second half of 2026 for first-line metastatic GEA.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The introduction of multiple generic versions of high-sodium oxybate is expected to negatively impact Xywav and Xyrem revenues, particularly in the second half of 2026.
• Market Dynamics: Potential payer negotiations and step edits could affect access to Xywav, although its unique low-sodium profile is expected to maintain its market position.
• Evolving Landscape: The sleep market is becoming increasingly competitive, with new wake-promoting agents entering the market, which could impact Xywav’s growth trajectory.

5. Notable Q&A Insights

• Xywav Dynamics: Management indicated that while the first half of 2026 may see minimal impact from generics, the second half could present challenges as generics build volume and new competitors enter the market.
• Epidiolex Growth Strategy: Emphasis on expanding into long-term care facilities and enhancing patient support programs to drive adult patient growth.
• Zanidatamab in Breast Cancer: The ongoing trial is positioned to potentially fill a significant treatment gap, with an estimated 150,000 HER2-positive breast cancer patients in the target market.
• Balance Sheet Leverage: Jazz is open to leveraging its balance sheet for strategic acquisitions but aims for a long-term reduction in debt as a part of its capital structure.

This earnings call highlighted Jazz Pharmaceuticals' strong financial performance and strategic initiatives while also addressing the challenges posed by competitive pressures in the market.